9.3亿美元市场！临床质谱多领域应用突破推动精准医疗发展

Core Insights - The article emphasizes the growing importance of clinical mass spectrometry in precision medicine, highlighting its unique advantages such as high specificity, sensitivity, and multi-parameter detection [3]. Market Overview - As of May 26, 2025, two clinical mass spectrometry instruments and twelve reagent kits have been approved. The global clinical mass spectrometry market is projected to reach $930 million by 2024, with an expected growth to $1.435 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9% [3]. Clinical Applications - Intraoperative Diagnosis of Brain Gliomas: The article discusses the use of portable mass spectrometry for rapid identification of IDH mutations in brain gliomas, which significantly improves patient prognosis. A study conducted by a team from Fudan University and other institutions achieved a 100% accuracy rate in detecting IDH mutations in 697 samples from 260 glioma patients [4]. - Therapeutic Drug Monitoring (TDM): Mass spectrometry is becoming a crucial tool in TDM, particularly for high-risk drugs like monoclonal antibodies. The nSMOL (nano-surface and molecular orientation limited) technology has enhanced specificity and sensitivity in measuring total drug concentrations, supporting personalized treatment for complex diseases [5]. Challenges and Future Directions - Despite the advancements, the transition of mass spectrometry from the laboratory to clinical settings faces challenges such as complex sample preparation, lack of standardized protocols, insufficient automation, and limitations in speed and cost. The article also mentions the importance of standard materials for ensuring accurate measurement in clinical chemistry [6].